Brief: Luye Pharma Receives Commercialization Rights To NHWA For 3 Injectable Antipsychotics In China
24/12/2025 10:18
Dec 24 (Reuters) - Luye Pharma Group Ltd 2186.HK: GRANT OF COMMERCIALIZATION RIGHTS TO NHWA FOR 3 LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN CHINA CERTAIN UNITS ENTERED AGREEMENT WITH JIANGSU NHWA HEXIN PHARMACEUTICAL MARKETING Further company coverage: 2186.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Luye Pharma
See all newsBrief: Luye Pharma Proposes Concurrent Repurchase Of US$180 MLN 6.25 Per Cent. Convertible Bonds Due 2028
Brief: Luye Pharma Group Posts FY Net Income Attributable RMB618.7 MLN
Brief: Luye Pharma Says Nanjing Xinan, Ningbo Cinda To Provide Further Capital To Nanjing Luye For RMB285 Mln
Brief: Luye Pharma Receives Commercialization Rights To NHWA For 3 Injectable Antipsychotics In China
Brief: Luye Pharma Says Approval Obtained For LY03017 For Clinical Trials In U.S.